Coagulation disorders are on top of the list of extracorporeal-membrane oxygenation (ECMO) complications. They contribute significantly to morbidity and mortality of ECMO patients. This observational study aims to evaluate coagulation profiles of ECMO patients treated on the intensive care units of the Department of Anaesthesiology of LMU Munich.
Coagulation disorders are on top of the list of extracorporeal-membrane oxygenation (ECMO) complications. They contribute significantly to morbidity and mortality of ECMO patients. This observational study aims to evaluate coagulation profiles of ECMO patients treated on the intensive care units of the Department of Anaesthesiology of LMU Munich. Adult ECMO patients are included in the study after informed consent. Bleeding and thromboembolic complications as well as treatment details are recorded. Additional coagulation laboratory markers (such as von-Willebrand-factor, ADAMTS13-protease, platelet function tests and thromboelastometric tests) are correlated with clinical signs of bleeding. Regular ultrasound examination of the large vessels are performed to Screen for thrombosis.
Study Type
OBSERVATIONAL
Enrollment
35
Department of Anesthesiology, LMU Munich
Munich, Germany
platelet function parameter
platelet function test
Time frame: after starting ECMO therapy - up to 28 days after starting ECMO therapy
platelet function parameter
platelet function test
Time frame: one week after ending ECMO therapy
coagulation parameter
thromboelastometric test
Time frame: after starting ECMO therapy - up to 28 days after starting ECMO therapy
coagulation parameter
thromboelastometric test
Time frame: one week after ending ECMO therapy
inflammatory parameter
bradykinin levels
Time frame: after starting ECMO therapy - up to 28 days after starting ECMO therapy
inflammatory parameter
bradykinin levels
Time frame: one week after ending ECMO therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.